210 related articles for article (PubMed ID: 29936477)
1. Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.
Iwamoto H; Izumi K; Natsagdorj A; Makino T; Nohara T; Shigehara K; Kadono Y; Mizokami A
In Vivo; 2018; 32(4):899-903. PubMed ID: 29936477
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
3. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
[TBL] [Abstract][Full Text] [Related]
5. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Holmes FA; Jones SE; O'Shaughnessy J; Vukelja S; George T; Savin M; Richards D; Glaspy J; Meza L; Cohen G; Dhami M; Budman DR; Hackett J; Brassard M; Yang BB; Liang BC
Ann Oncol; 2002 Jun; 13(6):903-9. PubMed ID: 12123336
[TBL] [Abstract][Full Text] [Related]
6. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.
Rimmer Y; Chester J; Joffe J; Stark D; Shamash J; Powles T; White J; Wason J; Parashar D; Armstrong G; Mazhar D; Williams MV
Br J Cancer; 2011 Sep; 105(6):766-72. PubMed ID: 21847130
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Yoshida Y; Komori K; Aoki M; Sandou M; Takagi M; Uejima E
Pharmazie; 2018 Oct; 73(10):613-616. PubMed ID: 30223928
[TBL] [Abstract][Full Text] [Related]
12. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
Kubo K; Miyazaki Y; Murayama T; Shimazaki R; Usui N; Urabe A; Hotta T; Tamura K
Br J Haematol; 2016 Aug; 174(4):563-70. PubMed ID: 27072050
[TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
Schuman SI; Lambrou N; Robson K; Glück S; Myriounis N; Pearson JM; Lucci JA
J Support Oncol; 2009; 7(6):225-8. PubMed ID: 20380330
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.
Nakagawa R; Iwamoto H; Makino T; Kadomoto S; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Front Oncol; 2021; 11():770067. PubMed ID: 35070973
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.
Pawloski PA; Larsen M; Thoresen A; Giordana MD
J Oncol Pharm Pract; 2016 Jun; 22(3):423-9. PubMed ID: 25956422
[TBL] [Abstract][Full Text] [Related]
18. Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.
Hayama T; Sakurai K; Miura K; Washinosu S; Tsuboi S; Uchiike A; Yoshida Y; Takei M
Int J Clin Pharm; 2018 Oct; 40(5):997-1000. PubMed ID: 29855985
[TBL] [Abstract][Full Text] [Related]
19. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study.
Chen CA; Lin H; Weng CS; Wen KC; Lu CH; Chou HH; Huang YF; Kang CY; Ho CM; Yu MH; Chou CY
Eur J Cancer; 2014 Dec; 50(18):3161-7. PubMed ID: 25459394
[TBL] [Abstract][Full Text] [Related]
20. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center.
Aurilio G; Verri E; Frassoni S; Bagnardi V; Cossu Rocca M; Cullurà D; Milani M; Mascia R; Curigliano G; Orsi F; Jereczek-Fossa BA; Musi G; Omodeo Salè E; De Cobelli O; Nolè F
Am J Clin Oncol; 2020 Jun; 43(6):381-387. PubMed ID: 32079853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]